EP1646353A4 - Fusion proteins for the treatment of cns - Google Patents
Fusion proteins for the treatment of cnsInfo
- Publication number
- EP1646353A4 EP1646353A4 EP04776038A EP04776038A EP1646353A4 EP 1646353 A4 EP1646353 A4 EP 1646353A4 EP 04776038 A EP04776038 A EP 04776038A EP 04776038 A EP04776038 A EP 04776038A EP 1646353 A4 EP1646353 A4 EP 1646353A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- cns
- treatment
- fusion proteins
- fusion
- proteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10184697.0A EP2354155B1 (en) | 2003-05-16 | 2004-05-17 | Fusion Proteins for Treatment of CNS |
EP17164945.2A EP3210999B1 (en) | 2003-05-16 | 2004-05-17 | Fusion proteins for treatment of cns |
ES17164945T ES2831031T3 (en) | 2003-05-16 | 2004-05-17 | Fusion proteins for CNS treatment |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47123903P | 2003-05-16 | 2003-05-16 | |
US47124003P | 2003-05-16 | 2003-05-16 | |
US47123603P | 2003-05-16 | 2003-05-16 | |
US47130003P | 2003-05-16 | 2003-05-16 | |
US47437203P | 2003-05-29 | 2003-05-29 | |
PCT/US2004/015661 WO2004110359A2 (en) | 2003-05-16 | 2004-05-17 | Fusion proteins for the treatment of cns |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17164945.2A Division EP3210999B1 (en) | 2003-05-16 | 2004-05-17 | Fusion proteins for treatment of cns |
EP10184697.0A Division EP2354155B1 (en) | 2003-05-16 | 2004-05-17 | Fusion Proteins for Treatment of CNS |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1646353A2 EP1646353A2 (en) | 2006-04-19 |
EP1646353A4 true EP1646353A4 (en) | 2008-06-04 |
Family
ID=33556640
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04776038A Ceased EP1646353A4 (en) | 2003-05-16 | 2004-05-17 | Fusion proteins for the treatment of cns |
EP10184697.0A Expired - Lifetime EP2354155B1 (en) | 2003-05-16 | 2004-05-17 | Fusion Proteins for Treatment of CNS |
EP17164945.2A Expired - Lifetime EP3210999B1 (en) | 2003-05-16 | 2004-05-17 | Fusion proteins for treatment of cns |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10184697.0A Expired - Lifetime EP2354155B1 (en) | 2003-05-16 | 2004-05-17 | Fusion Proteins for Treatment of CNS |
EP17164945.2A Expired - Lifetime EP3210999B1 (en) | 2003-05-16 | 2004-05-17 | Fusion proteins for treatment of cns |
Country Status (7)
Country | Link |
---|---|
EP (3) | EP1646353A4 (en) |
JP (5) | JP5399612B2 (en) |
AU (1) | AU2004247025B8 (en) |
CA (1) | CA2525782C (en) |
ES (1) | ES2831031T3 (en) |
MX (2) | MXPA05012306A (en) |
WO (1) | WO2004110359A2 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7666852B2 (en) * | 2002-04-22 | 2010-02-23 | Agenta Biotechnologies, Inc. | Wound and cutaneous injury healing with a nucleic acid encoding a proteoglycan polypeptide |
AU2003304173A1 (en) | 2002-05-04 | 2005-01-04 | Acorda Therapeutics, Inc. | Compositions and methods for promoting neuronal outgrowth |
US7429375B2 (en) | 2003-05-16 | 2008-09-30 | Acorda Therapeutics, Inc. | Proteoglycan degrading mutants for the treatment of CNS |
US7959914B2 (en) | 2003-05-16 | 2011-06-14 | Acorda Therapeutics, Inc. | Methods of reducing extravasation of inflammatory cells |
ES2411504T3 (en) * | 2004-05-18 | 2013-07-05 | Acorda Therapeutics, Inc. | Chondroitinase purification methods and stable formulations thereof |
WO2007038548A2 (en) | 2005-09-26 | 2007-04-05 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase abci mutants |
US8968728B2 (en) * | 2006-05-12 | 2015-03-03 | Bharat Biotech International Limited | Chimeric fusion proteins |
WO2007136042A1 (en) | 2006-05-19 | 2007-11-29 | Aichi Prefecture | Ameliorating agent for brain damage |
AU2007307736C1 (en) | 2006-10-10 | 2014-04-10 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase ABCI mutants |
RU2447449C2 (en) * | 2006-11-14 | 2012-04-10 | Дженентек, Инк. | Neuronal regeneration modulators |
WO2008149428A1 (en) * | 2007-06-05 | 2008-12-11 | Glycoscience Laboratories, Inc. | Therapeutic agent and preventive agent for autoimmune disease, inflammation and nerve disease |
EP3120863B1 (en) * | 2008-02-29 | 2020-05-06 | Acorda Therapeutics, Inc. | Compositions for achieving desired glial growth factor 2 plasma levels |
AU2015200220A1 (en) * | 2008-02-29 | 2015-02-12 | Acorda Therapeutics, Inc. | Method for achieving desired glial growth factor 2 plasma levels |
US20130143805A1 (en) * | 2010-08-13 | 2013-06-06 | Georgetown University | Ggf2 and methods of use |
JP5785619B2 (en) * | 2011-09-15 | 2015-09-30 | 生化学工業株式会社 | Skeletal muscle regeneration promoter |
GB201322396D0 (en) | 2013-12-18 | 2014-02-05 | Univ Nottingham | Transduction |
US11396529B2 (en) | 2020-11-12 | 2022-07-26 | National Sun Yat-Sen University | Isolated peptide, anti-cancer medicinal composition including the same and method of specifically reducing or inhibiting activities of cancer cells using the same |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000062067A1 (en) * | 1999-02-28 | 2000-10-19 | Washington University | Novel transduction molecules and methods for using same |
US6171575B1 (en) * | 1998-04-06 | 2001-01-09 | Shinichi Okuyama | Method of radioisotopic assessment of the integrity and function of the nose-brain barrier |
WO2002055684A2 (en) * | 2001-01-09 | 2002-07-18 | Univ Iowa Res Found | Synthetic proteins containing a protein transduction domain |
WO2002083179A2 (en) * | 2001-04-12 | 2002-10-24 | Bioaxone Therapeutique Inc. | Fusion proteins |
WO2003100031A2 (en) * | 2002-05-20 | 2003-12-04 | Board Of Regents, The University Of Texas System | Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues |
WO2004017044A2 (en) * | 2002-08-15 | 2004-02-26 | Acorda Therapeutics, Inc. | Chimeric protein |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5652122A (en) | 1989-12-21 | 1997-07-29 | Frankel; Alan | Nucleic acids encoding and methods of making tat-derived transport polypeptides |
US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
CA2161125A1 (en) * | 1993-04-23 | 1994-11-10 | Michael Joseph Ryan | Cloning and expression of the chondroitinase i and ii genes from p. vulgaris |
AU1176595A (en) * | 1993-11-12 | 1995-05-29 | International Technology Management Associates, Ltd. | Methods of repairing connective tissues |
JPH07316068A (en) * | 1994-05-25 | 1995-12-05 | Canji Inc | Tumor suppressor-fused protein |
GB9622500D0 (en) * | 1996-10-29 | 1997-01-08 | Oxford Biomedica Ltd | Therapeutic gene |
US20010006630A1 (en) * | 1997-09-02 | 2001-07-05 | Oron Yacoby-Zeevi | Introducing a biological material into a patient |
ES2313886T3 (en) * | 1999-03-16 | 2009-03-16 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | NEW CHEMICAL PROTEIN FOR THE PREVENTION AND TREATMENT OF HIV INFECTION. |
SE9901428D0 (en) * | 1999-04-21 | 1999-04-21 | Karolinska Innovations Ab | Amphibodies |
HU230159B1 (en) * | 1999-06-08 | 2015-09-28 | Regeneron Pharmaceuticals, Inc. | Vegf receptor chimeras for the treatment of eye disorders characterized by vascular permeability |
JP2004504262A (en) * | 1999-12-02 | 2004-02-12 | アイベックス テクノロジーズ, インコーポレイテッド | Attenuated fibroblast proliferation |
US7851447B2 (en) * | 2001-08-13 | 2010-12-14 | University Of Florida Research Foundation, Inc. | Methods for nerve repair |
GB0205022D0 (en) * | 2002-03-04 | 2002-04-17 | Univ Cambridge Tech | Materials and methods for the treatment of cns damage |
-
2004
- 2004-05-17 JP JP2006533212A patent/JP5399612B2/en not_active Expired - Fee Related
- 2004-05-17 ES ES17164945T patent/ES2831031T3/en not_active Expired - Lifetime
- 2004-05-17 MX MXPA05012306A patent/MXPA05012306A/en active IP Right Grant
- 2004-05-17 EP EP04776038A patent/EP1646353A4/en not_active Ceased
- 2004-05-17 WO PCT/US2004/015661 patent/WO2004110359A2/en active Application Filing
- 2004-05-17 EP EP10184697.0A patent/EP2354155B1/en not_active Expired - Lifetime
- 2004-05-17 CA CA2525782A patent/CA2525782C/en not_active Expired - Fee Related
- 2004-05-17 MX MX2012003710A patent/MX351062B/en unknown
- 2004-05-17 AU AU2004247025A patent/AU2004247025B8/en not_active Ceased
- 2004-05-17 EP EP17164945.2A patent/EP3210999B1/en not_active Expired - Lifetime
-
2012
- 2012-09-27 JP JP2012215041A patent/JP5656314B2/en not_active Expired - Fee Related
-
2014
- 2014-07-04 JP JP2014138911A patent/JP6141571B2/en not_active Expired - Fee Related
-
2017
- 2017-02-21 JP JP2017030467A patent/JP6913428B2/en not_active Expired - Lifetime
-
2020
- 2020-02-29 JP JP2020034479A patent/JP2020111578A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6171575B1 (en) * | 1998-04-06 | 2001-01-09 | Shinichi Okuyama | Method of radioisotopic assessment of the integrity and function of the nose-brain barrier |
WO2000062067A1 (en) * | 1999-02-28 | 2000-10-19 | Washington University | Novel transduction molecules and methods for using same |
WO2002055684A2 (en) * | 2001-01-09 | 2002-07-18 | Univ Iowa Res Found | Synthetic proteins containing a protein transduction domain |
WO2002083179A2 (en) * | 2001-04-12 | 2002-10-24 | Bioaxone Therapeutique Inc. | Fusion proteins |
WO2003100031A2 (en) * | 2002-05-20 | 2003-12-04 | Board Of Regents, The University Of Texas System | Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues |
WO2004017044A2 (en) * | 2002-08-15 | 2004-02-26 | Acorda Therapeutics, Inc. | Chimeric protein |
Non-Patent Citations (4)
Title |
---|
"ROUTE OF ADMINISTRATION - FDA", 11 January 2006 (2006-01-11), XP055243674 * |
BRADBURY E J ET AL: "Chondroitinase ABC promotes functional recovery after spinal cord injury", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 416, 11 April 2002 (2002-04-11), pages 636 - 640, XP002245003, ISSN: 0028-0836 * |
FROM WIKIPEDIA: "Route of administration", 5 January 2016 (2016-01-05), XP055243671 * |
MCGEE A W ET AL: "The Nogo-66 receptor: focusing myelin inhibition of axon regeneration", TRENDS IN NEUROSCIENCE, ELSEVIER, AMSTERDAM, NL, vol. 26, no. 4, April 2003 (2003-04-01), pages 193 - 198, XP004418152, ISSN: 0166-2236 * |
Also Published As
Publication number | Publication date |
---|---|
AU2004247025B2 (en) | 2011-06-23 |
EP2354155A2 (en) | 2011-08-10 |
JP5656314B2 (en) | 2015-01-21 |
CA2525782A1 (en) | 2004-12-23 |
CA2525782C (en) | 2019-02-05 |
WO2004110359A3 (en) | 2006-08-17 |
JP6141571B2 (en) | 2017-07-12 |
EP2354155B1 (en) | 2017-05-03 |
JP2014221793A (en) | 2014-11-27 |
JP5399612B2 (en) | 2014-01-29 |
JP2017125035A (en) | 2017-07-20 |
ES2831031T3 (en) | 2021-06-07 |
WO2004110359A2 (en) | 2004-12-23 |
EP3210999B1 (en) | 2020-08-26 |
MX351062B (en) | 2017-09-29 |
EP3210999A1 (en) | 2017-08-30 |
AU2004247025B8 (en) | 2011-06-30 |
EP2354155A3 (en) | 2011-09-07 |
AU2004247025A1 (en) | 2004-12-23 |
MXPA05012306A (en) | 2006-04-18 |
WO2004110359A9 (en) | 2006-02-16 |
JP2013049677A (en) | 2013-03-14 |
JP2020111578A (en) | 2020-07-27 |
JP2007516229A (en) | 2007-06-21 |
EP1646353A2 (en) | 2006-04-19 |
JP6913428B2 (en) | 2021-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL238540A0 (en) | Protein purification | |
IL166751A0 (en) | Modified transferin-antibody fusion proteins | |
EP1688439A4 (en) | Fused protein composition | |
IL173456A0 (en) | Process for the preparation of 4-amino-3-quinolinecarbonitriles | |
IL176384A0 (en) | Novel fused pyrrolocarbazoles | |
IL176385A0 (en) | Fused pyrrolocarbazoles and methods for the preparation thereof | |
EP1646353A4 (en) | Fusion proteins for the treatment of cns | |
IL176326A0 (en) | Process for the production of proteins | |
EP1549343A4 (en) | Method for the treatment of nephritis using anti-pdgf-dd antibodies | |
IL175743A0 (en) | Process for the preparation of thiazolopyrimidines | |
EP1578774A4 (en) | Protein purification | |
SI1656455T1 (en) | Process for the purification of recombinant polypeptides | |
ZA200605668B (en) | Fused pyrrolocarbazoles and methods for the preparation thereof | |
HK1095145A1 (en) | Process for the preparation of n-arylmorpholinones n- | |
PL371583A1 (en) | Process for the preparation of 7alpha-methylsteroids | |
SG111997A1 (en) | Improved process for the preparation of polyalkylphenoxyaminoalkanes | |
HK1087111A1 (en) | Process for the preparation of nicotinaldehydes | |
IL164788A0 (en) | Process for the preparation of 3-isochromanone | |
GB0522915D0 (en) | Methods for recombinant immunoglobulin treatment | |
PL376745A1 (en) | Process for the purification of tnf-binding proteins using imac | |
GB0311108D0 (en) | Proteins | |
HU0300255D0 (en) | Process for the preparation of 2-phenyl-4-methyl-1-tosil-piperazine | |
SI1673365T1 (en) | Process for the preparation of z-flupentixol | |
AU2003290331A8 (en) | Protein purification means | |
SI1395580T1 (en) | Method for the purification of triazolylmethylepoxides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20051214 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL HR LT LV MK |
|
PUAK | Availability of information related to the publication of the international search report |
Free format text: ORIGINAL CODE: 0009015 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12P 21/06 20060101AFI20061005BHEP |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: GRUSKIN, ELLIOTT, A. Inventor name: IACI, JENNIFER Inventor name: ROY, GARGI Inventor name: ZIMBER, MICHAEL, P. Inventor name: CAGGIANO, ANTHONY, O. |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20080506 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 38/51 20060101ALI20080425BHEP Ipc: C12N 9/88 20060101ALI20080425BHEP Ipc: C12P 21/06 20060101AFI20061005BHEP Ipc: C07K 14/475 20060101ALI20080425BHEP |
|
17Q | First examination report despatched |
Effective date: 20080905 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R003 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20160923 |